|
1
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar
|
|
2
|
Subbiah V and Kurzrock R: Phase 1 clinical
trials for sarcomas: The cutting edge. Curr Opin Oncol. 23:352–360.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fellenber J, Bernd L, Delling G, Witte D
and Zahlten-Hinguranage A: Prognostic significance of
drug-regulated genes in high-grade osteosarcoma. Mod Pathol.
20:1085–1094. 2007. View Article : Google Scholar
|
|
4
|
Chou AJ and Gorlick R: Chemotherapy
resistance in osteo-sarcoma: Current challenges and future
directions. Expert Rev Anticancer Ther. 6:1075–1085. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang L, Jin F, Qin A, et al: Targeting
Notch1 signaling pathway positively affects the sensitivity of
osteosarcoma to cisplatin by regulating the expression and/or
activity of Caspase family. Mol Cancer. 13:1392014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Abe S, Nishimoto Y, Isu K, Ishii T and
Goto T; Japanese Musculoskeletal Oncology Group: Preoperative
cisplatin for initial treatment of limb osteosarcoma: Its local
effect and impact on prognosis. Cancer Chemother Pharmacol.
50:320–324. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Anninga JK, Gelderblom H, Fiocco M, et al:
Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we
stand? Eur J Cancer. 47:2431–2445. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Uribe-Botero G, Russell WO, Sutow WW and
Martin RG: Primary osteosarcoma of bone. Clinicopathologic
investigation of 243 cases, with necropsy studies in 54. Am J Clin
Pathol. 67:427–435. 1977.PubMed/NCBI
|
|
9
|
Geller DS and Gorlick R: Osteosarcoma: A
review of diagnosis, management and treatment strategies. Clin Adv
Hematol Oncol. 8:705–718. 2010.
|
|
10
|
Nielsen JS and McNagny KM: The role of
podocalyxin in health and disease. J Am Soc Nephrol. 20:1669–1676.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Riccioni R, Calzolari A, Biffoni M, et al:
Podocalyxin is expressed in normal and leukemic monocytes. Blood
Cells Mol Dis. 37:218–225. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kelley TW, Huntsman D, McNagny KM,
Roskelley CD and Hsi ED: Podocalyxin: A marker of blasts in acute
leukemia. Am J Clin Pathol. 124:134–142. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yasuoka H, Tsujimoto M, Hirokawa M, et al:
Podocalyxin expression in undifferentiated thyroid carcinomas. J
Clin Pathol. 61:1228–1229. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hsu YH, Lin WL, Hou YT, et al: Podocalyxin
EBP50 ezrin molecular complex enhances the metastatic potential of
renal cell carcinoma through recruiting Rac1 guanine nucleotide
exchange factor ARHGEF7. Am J Pathol. 176:3050–3061. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sizemore S, Cicek M, Sizemore N, Ng KP and
Casey G: Podocalyxin increases the aggressive phenotype of breast
and prostate cancer cells in vitro through its interaction with
ezrin. Cancer Res. 67:6183–6191. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Somasiri A, Nielsen JS, Makretsov N, et
al: Overexpression of the anti-adhesin podocalyxin is an
independent predictor of breast cancer progression. Cancer Res.
64:5068–5073. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu H, Yang L, Liao D, Chen Y, Wang W and
Fang J: Podocalyxin regulates astrocytoma cell invasion and
survival against temozolomide. Exp Ther Med. 5:1025–1029.
2013.PubMed/NCBI
|
|
18
|
Ding X, Zhang Z, Li S and Wang A:
Combretastatin A4 phosphate induces programmed cell death in
vascular endothelial cells. Oncol Res. 19:303–309. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gu Y, Fan S, Xiong Y, et al: Cloning and
functional characterization of TCRP1, a novel gene mediating
resistance to cisplatin in an oral squamous cell carcinoma cell
line. FEBS Lett. 585:881–887. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cao CM, Zhang Y, Weisleder N, et al: MG53
constitutes a primary determinant of cardiac ischemic
preconditioning. Circulation. 121:2565–2574. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fos C, Salles A, Lang V, et al: ICOS
ligation recruits the p50alpha PI3K regulatory subunit to the
immunological synapse. J Immunol. 181:1969–1977. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li B, Yang Y, Jiang S, Ni B, Chen K and
Jiang L: Adenovirus-mediated overexpression of BMP-9 inhibits human
osteosarcoma cell growth and migration through downregulation of
the PI3K/AKT pathway. Int J Oncol. 41:1809–1819. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu ZL, Mao JH, Peng AF, et al: Inhibition
of fatty acid synthase suppresses osteosarcoma cell invasion and
migration via down-regulation of the PI3K/Akt signaling pathway in
vitro. Mol Med Rep. 7:608–612. 2013.
|
|
24
|
Zhao G, Cai C, Yang T, et al: MicroRNA-221
induces cell survival and cisplatin resistance through PI3K/Akt
pathway in human osteosarcoma. PLoS One. 8:e539062013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang TF, Wang H, Peng AF, et al:
Inhibition of fatty acid synthase suppresses U-2 OS cell invasion
and migration via downregulating the activity of HER2/PI3K/AKT
signaling pathway in vitro. Biochem Biophys Res Commun.
440:229–234. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fellenberg J, Kunz P, Sähr H and Depeweg
D: Overexpression of inosine 5′-monophosphate dehydrogenase type II
mediates chemo-resistance to human osteosarcoma cells. PLoS One.
5:e121792010. View Article : Google Scholar
|
|
27
|
Janeway KA and Grier HE: Sequelae of
osteosarcoma medical therapy: A review of rare acute toxicities and
late effects. Lancet Oncol. 11:670–678. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bruheim S, Xi Y, Ju J and Fodstad O: Gene
expression profiles classify human osteosarcoma xenografts
according to sensitivity to doxorubicin, cisplatin and ifosfamide.
Clin Cancer Res. 15:7161–7169. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yasuoka H, Tsujimoto M, Inagaki M, et al:
Clinicopathological significance of podocalyxin and phosphorylated
ezrin in uterine endometrioid adenocarcinoma. J Clin Pathol.
65:399–402. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Larsson A, Johansson ME, Wangefjord S, et
al: Overexpression of podocalyxin-like protein is an independent
factor of poor prognosis in colorectal cancer. Br J Cancer.
105:666–672. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Somasiri A, Nielsen JS, Makretsov N, et
al: Overexpression of the anti-adhesin podocalyxin is an
independent predictor of breast cancer progression. Cancer Res.
64:5068–5073. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu M, Wang J, Huang H, et al:
miR-181a-Twist1 pathway in the chemoresistance of tongue squamous
cell carcinoma. Biochem Biophys Res Commun. 441:364–370. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tsai HC, Huang CY, Su HL and Tang CH: CCN2
enhances resistance to cisplatin-mediating cell apoptosis in human
osteo-sarcoma. PLoS One. 9:e901592014. View Article : Google Scholar
|
|
34
|
Rosenberg B, Vancamp L, Trosko JE and
Mansour VH: Platinum compounds: A new class of potent antitumour
agents. Nature. 222:385–386. 1969. View
Article : Google Scholar : PubMed/NCBI
|
